Purpose: A clinical study to characterize renal masses with positron emission tomography/computed tomography (PET/CT) was undertaken.
Patients And Methods: This was an open-label multicenter study of iodine-124 ((124)I) -girentuximab PET/CT in patients with renal masses who were scheduled for resection. PET/CT and contrast-enhanced CT (CECT) of the abdomen were performed 2 to 6 days after intravenous (124)I-girentuximab administration and before resection of the renal mass(es). Images were interpreted centrally by three blinded readers for each imaging modality. Tumor histology was determined by a blinded central pathologist. The primary end points-average sensitivity and specificity for clear cell renal cell carcinoma (ccRCC)-were compared between the two modalities. Agreement between and within readers was assessed.
Results: (124)I-girentuximab was well tolerated. In all, 195 patients had complete data sets (histopathologic diagnosis and PET/CT and CECT results) available. The average sensitivity was 86.2% (95% CI, 75.3% to 97.1%) for PET/CT and 75.5% (95% CI, 62.6% to 88.4%) for CECT (P = .023). The average specificity was 85.9% (95% CI, 69.4% to 99.9%) for PET/CT and 46.8% (95% CI, 18.8% to 74.7%) for CECT (P = .005). Inter-reader agreement was high (κ range, 0.87 to 0.92 for PET/CT; 0.67 to 0.76 for CECT), as was intrareader agreement (range, 87% to 100% for PET/CT; 73.7% to 91.3% for CECT).
Conclusion: This study represents (to the best of our knowledge) the first clinical validation of a molecular imaging biomarker for malignancy. (124)I-girentuximab PET/CT can accurately and noninvasively identify ccRCC, with potential utility for designing best management approaches for patients with renal masses.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5795663 | PMC |
| http://dx.doi.org/10.1200/JCO.2011.41.2445 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinicopathological features and molecular genetic changes of primary renal hemangioblastoma, a TSC-associated tumor.
Pathol Res Pract
January 2025
Department of Orthopaedics, the second Affiliated Hospital of Wannan Medical College, Wuhu 241000, China. Electronic address:
Background: Renal hemangioblastoma (HB) is a rare extra-central nervous system (CNS) tumor, typically not linked to Von Hippel-Lindau (VHL) Syndrome, and its underlying genetic drivers and molecular mechanisms remain elusive. The objective of this study is to investigate the clinicopathological features and molecular genetic changes of primary renal hemangioblastomas.
Methods: Herein, the clinical, imaging, clinicopathological features, and immunophenotype in 3 cases of renal HB were retrospectively analyzed.
Can parenchymal volume analysis replace nuclear renal scans for split renal function before and after partial nephrectomy with warm ischemia?
Urol Oncol
January 2025
Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China; State Key Laboratory of Oncology in Southern China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China; State Key Laboratory of Oncology in Southern China, Guangzhou, P. R. China. Electronic address:
Article Synopsis
- The study evaluates parenchymal volume analysis (PVA) as a potential alternative to nuclear renal scan (NRS) for assessing split renal function (SRF) before and after partial nephrectomy (PN) with warm ischemia.
- Preoperatively, PVA showed a strong correlation with NRS findings, indicating its reliability for SRF assessment (49.4% vs. 50.0%, P = .501).
- Results suggest that while PVA is consistent with NRS preoperatively, the efficacy of PVA remains uncertain for post-operative SRF evaluation after PN, indicating a need for further investigation.
Tailoring Renal Mass Biopsy: Optimal Core Number and Location Based on Tumor Size for Enhanced Diagnostic Accuracy- A Prospective Ex-Vivo Study.
Urology
January 2025
Urology Department, Shohada-e-Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address:
Objective: To determine the optimal number and location of biopsy cores in renal masses based on mass size in order to maximize diagnostic accuracy.
Methods: This observational study included 360 patients with renal masses, who were divided equally into six groups. Each group was matched in terms of mass size (mass size category: ≤ 4 cm (T1a), 4-7 cm (T1b), 7-10 cm (T2a), and > 10 cm (T2b)).
Cold agglutinin syndrome as a precursor for the diagnosis of low‑grade lymphoma: A case report.
Med Int (Lond)
December 2024
Department of Hematology, Dokuz Eylul University Hospital, Izmir 35000, Turkey.
Cold agglutinin syndrome is a form of acquired hemolytic anemia that typically arises from underlying conditions, such as infections, autoimmune disorders or lymphoid malignancies. The majority of patients remain asymptomatic and are diagnosed with anemia through routine complete blood count (CBC) testing. The present study describes the case of a male patient in his 50s who sought a second opinion at the authors' clinic due to newly detected anemia.
View Article and Find Full Text PDFPercutaneous cryoablation of renal tumours under computed tomography guidance: methodology of the procedure.
Pol J Radiol
November 2024
University Center of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland.
Purpose: The incidence of renal cell carcinoma has been steadily increasing over the past two decades, raising the need for minimally invasive approaches. We sought to present the methodology of the percutaneous cryoablation (PCA) procedure developed based on one year of experience with 81 PCA procedures.
Material And Methods: The percutaneous cryoablation programme at Wroclaw Medical University Hospital has been successfully operating for a year.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!